nagilactone c has been researched along with Aortic Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Gui, Y; Hu, L; Li, H; Wang, Y; Xi, C; Yan, H; Yao, S; Ye, Y; Yu, C | 1 |
1 other study(ies) available for nagilactone c and Aortic Diseases
| Article | Year |
|---|---|
A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.
Topics: Animals; Aorta; Aortic Diseases; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Binding Sites; Cell Line, Tumor; Cholesterol, HDL; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Humans; Hypolipidemic Agents; Liver X Receptors; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Phenotype; Plaque, Atherosclerotic; Promoter Regions, Genetic; RAW 264.7 Cells; RNA Interference; Signal Transduction; Transfection | 2016 |